The
Sign up for free.
The German Lymphoma Alliance e.V. (GLA) is a non-profit association dedicated to the sustainable improvement of therapy outcomes for patients with malignant lymphomas in Germany[1][2]. As a central platform, the GLA bundles and coordinates expertise in research, diagnostics and treatment, with a strong focus on Non-Hodgkin lymphomas[1][2][3].
The GLA merges the long-standing activities of leading study groups: the Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome (DSHNHL), the Deutsche Studiengruppe für niedrigmaligne Lymphome (GLSG e.V.), the Arbeitsgruppe Lymphome der Ostdeutschen Studiengruppe für Hämatologie und Onkologie (OSHO) and in cooperation with the [1][2]. This creates an independent organization for [1][2][3].
The central services include:
The GLA cooperates with renowned clinics throughout Germany, including university hospitals in München, Berlin, Münster, Heidelberg and many more, to optimize therapies[6].
The main mission of the GLA is: Bundling national expertise to raise treatment standards and improve patient outcomes - especially in Non-Hodgkin lymphomas[1][2]. Core values are independence, scientific rigor and patient proximity: As an association, it promotes an active research platform that connects basic and clinical research. The board, led by President Prof. Dr. Martin Dreyling and President Elect Prof. Dr. Georg Lenz, drives these goals forward[3][5][6]. The GLA invites membership, donations and study submissions to strengthen the network[9][10].
Although primarily research-oriented, the GLA integrates sustainable initiatives through long-term registry management and continuous study updates (e.g. CLEAR study 2024)[4][6]. The goal: To establish evidence-based therapies that use resources efficiently and increase survival rates. Publications and scores contribute to global knowledge transfer[7][9]. Current developments include biomarker programs and MRD analyses for personalized medicine[5].
The GLA stands as a beacon of lymphoma research in Germany: Through cooperation and innovation, it improves the lives of those affected every day. Become part of this commitment - for better therapies tomorrow[1][2].
(Total length: approx. 2480 characters incl. spaces)
